Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Classic: XELOX in Gastric Cancer
NCT01880632Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2013
- Primary completion
- May 2016
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in gastric adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT01880632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01880632.